The fund is managed based on the Dow Jones U.S. Select Pharmaceuticals Index to track the performance of the US pharmaceutical industry. Its main holdings are the global pharmaceutical giants that lead new drug development and vaccine production.

Within the healthcare sector, it suits investors who look specifically for the long-term growth potential and dividend stability of pharmaceuticals.

It is a passively managed (index-tracking) ETF launched by iShares in 2006.

The fund holds US-listed pharmaceutical companies in order of market capitalization, applying a cap so that no single stock's weighting becomes excessive. This moderates concentration in a handful of large industry names while still following the broader movement of the sector.

• Pure exposure specialized in the US pharmaceutical sector
• Portfolio centered on large drugmakers with stable cash flows

Assets under management (AUM) stand at $1.6B, and the expense ratio is 0.37% per year.

Whereas VFH and VIS shown in the table represent the financial and industrial sectors, IHE focuses solely on the pharmaceutical industry, which has strong defensive characteristics while also carrying new-drug momentum.

Rising demand for medicines driven by population aging and the launch of innovative new drugs have produced a long-term upward trend. Whenever concerns about an economic slowdown emerge, its appeal as a defensive investment tends to stand out, and it has a tendency to deliver stable performance.

Capital has been flowing into the fund as a lower-volatility alternative to biotech within the healthcare sector, and investor sentiment tends to improve during periods when large drugmakers report solid earnings.

Its strengths are the stable profitability and defensive nature of large drugmakers, while high concentration in specific stocks and regulatory risk are factors to consider.

FV shown in the table is a strategy that blends multiple sectors. If you want to invest in healthcare as a whole, XLV or VHT can serve as broad alternatives. If you want the more aggressive biotech space, you can consider IBB or XBI. If you want to focus on a specific theme such as medical devices, IHI is also a good option.

These are the key items to verify before investing in IHE. It is important to carefully review the earnings structure specific to the pharmaceutical industry and the concentration in top holdings, and to reflect them in your investment portfolio.

Pharmaceutical stocks can see very large swings in individual companies depending on patent expirations and new drug approvals. Also, because the weightings of the top companies are high, note that the entire fund can fluctuate sharply depending on their earnings releases.

It is a sector-focused product suited to investors who believe in the stable growth of large US drugmakers. It is useful for adding a defensive character to a portfolio while also expecting the upside of new drug development.